On #InternationalRareDiseaseDay 2026, we are proud to join the global movement to recognise the 300 million people worldwide living with a rare disease.

At Orphelia Pharma, our commitment has always focused on developing and delivering innovative medicines tailored to the specific needs of children living with serious conditions, particularly oncology.

Since joining @Orphalan in December 2025, we have become part of a global rare disease platform that strengthens our ability to bring innovative therapies to the children and families who need them most. This week, our colleagues proudly joined the #RunForRare initiative – a powerful reminder of the passion and purpose that drive our work every day.

#InternationalRareDiseaseDay #Eurodis #MoreThanYouCanImagine #RunForRare

GL-ORPH-CORP-26006 | February 2026